70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 4, 2011, Pages 1056-1063

  Beckendorf, Véronique ^a   Guerif, Stéphane ^b   Le Prisé, Elisabeth ^c   Cosset, Jean Marc ^d   Bougnoux, Agnes ^e   Chauvet, Bruno ^f   Salem, Naji ^g   Chapet, Olivier ^h   Bourdain, Sylvain ⁱ   Bachaud, Jean Marc ^j   Maingon, Philippe ^k   Hannoun Levi, Jean Michel ^l   Malissard, Luc ^m   Simon, Jean Marc ⁿ   Pommier, Pascal ^o   Hay, Men ^p   Dubray, Bernard ^q   Lagrange, Jean Léon ^r   Luporsi, Elisabeth ^a   Bey, Pierre ^d  

^a CENTRE ALEXIS VAUTRIN   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c Centre Eugne Marquis   (France)

^d INSTITUT CURIE   (France)

^e CHU BRETONNEAU   (France)

^f INSTITUT SAINTE CATHERINE   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ CENTRE RENÉ GAUDUCHEAU   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k Georges Franois Leclerc Cancer Center   (France)

^l CENTRE ANTOINE LACASSAGNE   (France)

^m La Chaussée Saint Victor ^*  (France)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o CENTRE LÉON BÉRARD   (France)

^p CENTRE VAL D AURELLE   (France)

^q CENTRE HENRI BECQUEREL   (France)

^r HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Conformal radiotherapy; Dose escalation; Prostate cancer; Randomized trial

Indexed keywords

AFTER-TREATMENT; ANDROGEN DEPRIVATION; BIOCHEMICAL OUTCOME; CONFORMAL RADIOTHERAPY; DOSE ESCALATION; HIGH DOSE; LATE EFFECTS; LOCALIZED PROSTATE CANCER; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; QUALITY OF LIFE; RADIATION THERAPY ONCOLOGY GROUPS; RANDOMIZED TRIAL; RECTAL TOXICITY; RELAPSE RATES; THERAPEUTIC RADIOLOGY;

ONCOLOGY; RADIATION EFFECTS; RADIOLOGY; RADIOTHERAPY; SURVEYS; TISSUE; TOXICITY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLADDER INJURY; CANCER RADIOTHERAPY; CANCER RELAPSE; COMORBIDITY; CONTROLLED STUDY; FOLLOW UP; HUMAN; LOCALIZED PROSTATE CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE; QUESTIONNAIRE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RECTUM INJURY; URINARY TRACT INJURY;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LIBIDO; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; TREATMENT OUTCOME; URINARY BLADDER;

EID: 79959335126     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.03.049     Document Type: Article

References (40)

1. G.K. Zagars, A. Pollack, and A.C. von Eschenbach Prostate cancer and radiation therapy - The message conveyed by serum prostate-specific antigen Int J Radiat Oncol Biol Phys 33 1995 23 35
2. A.L. Zietman, J.J. Coen, and K.C. Dallow The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome Int J Radiat Oncol Biol Phys 32 1995 287 292
3. G.E. Hanks, K.L. Martz, and J.J. Diamond The effect of dose on local control of prostate cancer Int J Radiat Oncol Biol Phys 15 1988 1299 1305 (Pubitemid 19015470)
4. A. Pollack, and G.K. Zagars External beam radiotherapy dose response of prostate cancer Int J Radiat Oncol Biol Phys 39 1997 1011 1018 (Pubitemid 27506151)
5. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500 (Pubitemid 28275076)
6. P. Bey, C. Carrie, and V. Beckendorf Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer - Preliminary results Int J Radiat Oncol Biol Phys 48 2000 513 517
7. P. Bey, C. Carrie, and C. Ginestet French study of dose escalation from 66 to 80 Gy with 3D-CRT in prostate cancer: Results at 5 years. 45th Annual ASTRO Meeting (Abstract 1018) Int J Radiat Oncol Biol 57 Suppl. 2 2003 S272
8. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
9. D.P. Dearnaley, E. Hall, and D. Lawrence Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects Br J Cancer 92 2005 488 498 (Pubitemid 40395529)
10. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487 (Pubitemid 46805903)
11. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
12. A. Al-Mamgani, W.L. van Putten, and W.D. Heemsbergen Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
13. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383 (Pubitemid 17055592)
14. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
15. A.W. Partin, M.W. Kattan, and E.N. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451 (Pubitemid 27208886)
16. V. Beckendorf, S. Guerif, and E. Le Prise The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity Int J Radiat Oncol Biol Phys 60 2004 1056 1065 (Pubitemid 39440789)
17. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement: Guidelines for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041
18. M. Roach III, G.E. Hanks, and H.J. Thames Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
19. C.A. Lawton, M. Won, and M.V. Pilepich Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706 Int J Radiat Oncol Biol Phys 21 1991 935 939
20. LENT-SOMA scales for all anatomic sites Int J Radiat Oncol Biol Phys 31 1995 1049 1091
21. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376 (Pubitemid 23073154)
22. D. Osoba, G. Rodrigues, and J. Myles Interpreting the significance of change in health-related quality-of-life scores J Clin Oncol 16 1998 139 144 (Pubitemid 28041591)
23. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Amer Statist Assn 53 1958 457 481
24. L.J. Boersma, M. van den Brink, and A.M. Bruce Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms Int J Radiat Oncol Biol Phys 41 1998 83 92 (Pubitemid 28211306)
25. V. Beckendorf, S. Guerif, and E. Le Prise Late toxicity in the GETUG 06 randomized trial comparing 70 Gy and 80 Gy for localized prostate cancer Int J Radiat Oncol Biol Phys 69 2007 S319
26. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era Cancer 95 2002 281 286 (Pubitemid 34787593)
27. S.A. Wilson, and D.K. Rex Endoscopic treatment of chronic radiation proctopathy Curr Opin Gastroenterol 22 2006 536 540 (Pubitemid 44197529)
28. M.R. Cheung, S.L. Tucker, and L. Dong Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 1059 1065
29. M. Ferrer, J.F. Suarez, and F. Guedea Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 421 432
30. M.G. Sanda, R.L. Dunn, and J. Michalski Quality of life and satisfaction with outcome among prostate-cancer survivors N Engl J Med 358 2008 1250 1261 (Pubitemid 351439226)
31. I. Lips, H. Dehnad, and A.B. Kruger Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study Int J Radiat Oncol Biol Phys 69 2007 656 661 (Pubitemid 47418401)
32. P.A. Kupelian, C.A. Reddy, and E.A. Klein Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life Int J Radiat Oncol Biol Phys 51 2001 988 993 (Pubitemid 33026429)
33. D.J. Little, D.A. Kuban, and L.B. Levy Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study Urology 62 2003 707 713 (Pubitemid 37205010)
34. P.C. Albertsen, J.A. Hanley, and D.F. Gleason Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975 980 (Pubitemid 28445095)
35. G. Borghede, and M. Sullivan Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy: Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30 Qual Life Res 5 1996 212 222 (Pubitemid 26180669)
36. S.T. Peeters, W.D. Heemsbergen, and W.L. van Putten Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy Int J Radiat Oncol Biol Phys 61 2005 1019 1034 (Pubitemid 40340897)
37. T. Messai, R. Itti, and C. Tayeb Factors associated with rectal bleeding in prostate cancer radiotherapy Int J Radiat Oncol Biol Phys 69 2007 S340 S341
38. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295 (Pubitemid 351159365)
39. A.V. D'Amico, J. Manola, and M. Loffredo Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial JAMA 292 2004 821 827 (Pubitemid 39079668)
40. T.E. Schultheiss, W.R. Lee, and M.A. Hunt Late GI and GU complications in the treatment of prostate cancer Int J Radiat Oncol Biol Phys 37 1997 3 11 (Pubitemid 27090129)